Diffusion of specific recommendations, addressing all the elements of the use of LAI antipsychotics, will boost clinicians’ perceived competence. It can also assist to increase the percentage of sufferers to whom LAI antipsychotics is going to be supplied by psychiatrists as a therapeutic selection. The objective of those suggestions is usually to propose a prescription framework to clinicians for the use of a certain formulation of antipsychotics (LAI) in diverse therapeutic indications and specific clinical circumstances. The aim is always to enable clinicians to present one of the most proper pharmaceutical strategies towards the patients and to facilitate the usage of LAI antipsychotics in clinical practice. The suggestions presented right here from a consensus-based guidelines methodology (Formal Consensus Recommendations) arebased on scientific information plus the consensus of a panel of experts.MethodsQuestionnaire developmentInitially, we performed an evaluation and also a literature assessment concerning the indications plus the use of LAI antipsychotics. A literature search get Valine angiotensin II utilizing the key phrases “antipsychotic”, “neuroleptic”, “first-generation antipsychotic”, “atypical antipsychotic”, “second-generation antipsychotic”, “long-acting injectable”, “depot”, “depot neuroleptic” was performed in PubMed and EMBASE to seek out all of the relevant research published. Further references had been identified from http:www.fda.gov and http: www.ema.europa.eu. Data from all of those sources was discussed and an overview with the present proof has been graded and summarized applying the French National Authority for Well being (HAS) “levels of evidence” criteria [16]. Following this 1st step, the scientific committee (PML, LS, MA, Pc, SG, SL) created a questionnaire consisting of 32 questions that covered 539 therapeutic choices. The 32 queries have been regrouped into 3 areas PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21310042 that were judged as necessary: Target-population: Description on the different indications from the LAI antipsychotics and with the most appropriate period from the illness to introduce the therapy. Prescription and use: Option of your molecule, methods of introduction, specific strategies depending on the psychiatric disorder or comorbidities, and therapy monitoring. Distinct population: Use of LAI antipsychotics in pregnant girls, elderly individuals, subjects within a precarious circumstance, and subjects obtaining to be treated in a prison establishment. This questionnaire was made to be completed by an experts’ panel. The time essential for its administration was estimated at about 3 hours. In the time of improvement, all of the LAI antipsychotics out there in France have been proposed as therapeutic choices (Table 1). They were regrouped into two categories: Long-acting injectable first-generation antipsychotics (LAI FGA). Long-acting injectable second-generation antipsychotics (LAI SGA). This artificial separation FGASGA is not consensual on account of their heterogeneous profiles of efficacyLlorca et al. BMC Psychiatry 2013, 13:340 http:www.biomedcentral.com1471-244X13Page three ofTable 1 LAI antipsychotics available in France (when the survey was completed)LAI second-generation antipsychotics LAI first-generation antipsychotics Risperidone microsphere Olanzapine pamoate Haloperidol decanoate Zuclopenthixol decanoate Flupentixol decanoate Fluphenazine decanoate Pipotiazine palmitateNote: as paliperidone palmitate had a advertising authorization date soon after the development of these guidelines, it couldn’t be taken into account.Specialist selectionThe Scientific Committee (Appendix 1) sel.